Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer

Oncology (Switzerland)

Volumn 84, Issue 3, 2013, Pages 166-173

  Rahman, Mohammed Tanjimur ^a   Nakayama, Kentaro ^a   Ishikawa, Masako ^a   Rahman, Munmun ^a   Katagiri, Hiroshi ^a   Katagiri, Atsuko ^a   Ishibashi, Tomoka ^a   Iida, Kouji ^a   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Endometrioid endometrial cancer; Estrogen receptor; Fatty acid synthase; Progesterone receptor

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FATTY ACID SYNTHASE; PACLITAXEL; PROGESTERONE RECEPTOR; DIMETHYL SULFOXIDE; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; ENDOMETRIOID ENDOMETRIAL CANCER; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; ENDOMETRIAL CANCER CELL LINE; ENZYME INHIBITION; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL;

4-BUTYROLACTONE; BLOTTING, WESTERN; CARCINOMA, ENDOMETRIOID; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FATTY ACID SYNTHETASE COMPLEX, TYPE I; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84873299231     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342967     Document Type: Article

References (26)

1. Pisani P, Bray F, Parkin DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002; 97: 72-81.
2. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P: Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann NY Acad Sci 2001; 943: 296-315. (Pubitemid 32928322)
3. Hecht JL, Mutter GL: Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24: 4783-4791. (Pubitemid 46630943)
4. Prat J, Gallardo A, Cuatrecasas M, Catasus L: Endometrial carcinoma: pathology and genetics. Pathology 2007; 39: 72-87.
5. Menendez JA, Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-777. (Pubitemid 47469806)
6. Kuhajda FP: Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66: 5977-5980.
7. Jin Q, Yuan LX, Boulbes D, Baek JM, Wang YN, Gomez-Cabello D, Hawke DH, Yeung SC, Lee MH, Hortobagyi GN, Hung MC, Esteva FJ: Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 2010; 12:R96.
8. Wan HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR: Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005; 24: 3574-3582. (Pubitemid 40756227)
9. Flavin R, Zadra G, Loda M: Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011; 223: 283-294.
10. Ishimura N, Amano Y, Sanchez-Siles AA, Fukuhara H, Takahashi Y, Uno G, Tamagawa Y, Mishima Y, Yuki T, Ishihara S, Kinoshita Y: Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis. J Clin Gastroenterol 2011; 45: 665-672.
11. Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, Al-Nuaim A, Al-Sobhi S, Al-Dayel F, Bavi P, Hussain AR, Al-Kuraya KS: Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab 2008; 93: 4088-4097.
12. Uddin S, Hussain AR, Ahmed M, Abubaker J, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS: High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. Am J Gastroenterol 2009; 104: 1790-1801.
13. Pizer ES, Lax SF, Kuhajda FP, Pasternack GR, Kurman RJ: Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer 1998; 83: 528-537. (Pubitemid 28354509)
14. Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJ, Wang TL, Shih Ie M: A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 2006; 103: 18739-18744. (Pubitemid 44913480)
15. Nakayama K, Miyazaki K, Kanzaki A, Fukumoto M, Takebayashi Y: Expression and cisplatin sensitivity of copper-transporting Ptype adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol Rep 2001; 8: 1285-1287. (Pubitemid 33758731)
16. Alo PL, Visca P, Framarino ML, Botti C, Monaco S, Sebastiani V, Serpieri DE, Di Tondo U: Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 2000; 7: 1383-1388.
17. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002; 98: 19-22. (Pubitemid 34113412)
18. Kusakabe T, Nashimoto A, Honma K, Suzuki T: Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology 2002; 40: 71-79. (Pubitemid 34107384)
19. Sebastiani V, Visca P, Botti C, Santeusanio G, Galati GM, Piccini V, Capezzone de Joannon B, Di Tondo U, Alo PL: Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol Oncol 2004; 92: 101-105. (Pubitemid 38147378)
20. Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H: Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998; 69: 220-225. (Pubitemid 28289963)
21. Gehrig PA, Van Le L, Olatidoye B, Geradts J: Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999; 86: 2083-2089.
22. Lupu R, Menendez JA: Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators? Endocrinology 2006; 147: 4056-4066. (Pubitemid 44274975)
23. Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang TL, Visvanathan K, Kuhajda FP, Bristow RE, Zhang H, Shih Ie M: Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncol 2010; 2010: 285191.
24. McKenna NJ, Lanz RB, O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999; 20: 321-344. (Pubitemid 30649811)
25. McKenna NJ, O'Malley BW: From ligand to response: generating diversity in nuclear receptor coregulator function. J Steroid Biochem Mol Biol 2000; 74: 351-356. (Pubitemid 32126246)
26. Rachez C, Freedman LP: Mediator complexes and transcription. Curr Opin Cell Biol 2001; 13: 274-280. (Pubitemid 32429491)